DAC

MOMA Data Access Committee

Dac ID Contact Person Email Access Information
EGAC00001000145 Jakob Skou Pedersen JAKOB [dot] SKOU [at] KI [dot] AU [dot] DK

This DAC controls 21 datasets:

Dataset ID Description Technology Samples
EGAD00010000514 Case samples using SNP 6.0 Array GenomeWideSNP_6-BirdseedV2 12
EGAD00010000510 Matched control samples using HumanOmni1-Quad GenomeWideSNP_6-BirdseedV2 12
EGAD00010000512 Case samples using HumanOmni1-Quad GenomeWideSNP_6-BirdseedV2 12
EGAD00001000711 Illumina HiSeq 2000; 42
EGAD00001000713 Illumina HiSeq 2000; 12
EGAD00001000712 Illumina HiSeq 2000; 72
EGAD00001000830 Illumina HiSeq 2000; 14
EGAD00001000834 Illumina HiSeq 2000; 20
EGAD00001000833 Illumina HiSeq 2000; 10
EGAD00001000832 Illumina HiSeq 2000; 16
EGAD00001000829 Illumina HiSeq 2000; 16
EGAD00001000831 Illumina HiSeq 2000; 30
EGAD00001000835 Illumina HiSeq 2000; 8
EGAD00001001941 Variants derived from mapped whole transcriptome RNA-Seq data from 476 human samples of early stage urothelial carcinoma. 476
EGAD00010000508 Matched control samples using SNP 6.0 Array GenomeWideSNP_6-BirdseedV2 12
EGAD00001001939 Mapped whole transcriptome RNA-Seq data from 476 human samples of early stage urothelial carcinoma. Illumina HiSeq 2000; 476
EGAD00001001940 Un-mapped whole transcriptome RNA-Seq data from 476 human samples of early stage urothelial carcinoma. Illumina HiSeq 2000; 476
EGAD00001002717 In this study we characterized genomic alterations in two to five metachronous bladder tumors from 29 patients initially diagnosed with early stage disease. Fourteen patients (32 tumors) had non progressive disease (NPD) and 15 patients (34 tumors) had progressive disease (PD). Whole exome sequencing (WES, ~50x mean read depth and whole transcriptome RNA-seq was performed (RNA was not advalible for 4 tumors). Data provided here consist of 71 unmapped Bam files form whole transcriptome RNA-seq. Illumina HiSeq 2000;ILLUMINA 71
EGAD00001002718 In this study we characterized genomic alterations in two to five metachronous bladder tumors from 29 patients initially diagnosed with early stage disease. Fourteen patients (32 tumors) had non progressive disease (NPD) and 15 patients (34 tumors) had progressive disease (PD). Whole exome sequencing (WES, ~50x mean read depth and whole transcriptome RNA-seq was performed (RNA was not advalible for 4 tumors). Data provided here consist of 71 mapped Bam files form whole transcriptome RNA-seq. Illumina HiSeq 2000;ILLUMINA 71
EGAD00001002772 In this study we characterized genomic alterations in three bladder cancer patients with metastatic disease courses. Multiple regions were procured by laser microdissection or punctures from primary tumor, lymph node metastases and from distant metastases. Data provided here consist of 35 Bam files for WES (32 Tumors and 2 blood, 1 adjacent normal) NextSeq 500;ILLUMINA 35
EGAD00001002716 In this study we characterized genomic alterations in two to five metachronous bladder tumors from 29 patients initially diagnosed with early stage disease. Fourteen patients (32 tumors) had non progressive disease (NPD) and 15 patients (34 tumors) had progressive disease (PD). Whole exome sequencing (WES, ~50x mean read depth and whole transcriptome RNA-seq was performed (RNA was not advalible for 4 tumors) Data provided here consist of 122 Bam files for WES (83 Tumors and 39 blood) Illumina HiSeq 2000;ILLUMINA 122